Vor Biopharma (NYSE:VOR) Major Shareholder Sells $637,000.00 in Stock

Key Points

• Reprogrammed Interchange LLC, a major shareholder of Vor Biopharma, sold 350,000 shares at an average price of $1.82, totaling approximately $637,000, which decreased their ownership by 1.01%.
• Vor Biopharma's stock price decreased to $1.80 following multiple sales by the insider, with a market cap of $228.03 million and an average target price of $6.07 according to analysts.
• Institutional investors continue to show interest in Vor Biopharma, with 97.29% of the stock currently owned by institutional investors and hedge funds.

Vor Biopharma Inc. (NYSE:VOR - Get Free Report) major shareholder Reprogrammed Interchange Llc sold 350,000 shares of the company's stock in a transaction dated Wednesday, September 10th. The stock was sold at an average price of $1.82, for a total transaction of $637,000.00. Following the completion of the transaction, the insider owned 34,213,292 shares in the company, valued at $62,268,191.44. This represents a 1.01% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Large shareholders that own at least 10% of a company's stock are required to disclose their sales and purchases with the SEC.

Reprogrammed Interchange Llc also recently made the following trade(s):

• On Monday, September 15th, Reprogrammed Interchange Llc sold 400,000 shares of Vor Biopharma stock. The stock was sold at an average price of $1.64, for a total transaction of $656,000.00.
• On Friday, September 12th, Reprogrammed Interchange Llc sold 300,000 shares of Vor Biopharma stock. The stock was sold at an average price of $1.75, for a total transaction of $525,000.00.
• On Thursday, September 11th, Reprogrammed Interchange Llc sold 284,805 shares of Vor Biopharma stock. The stock was sold at an average price of $1.83, for a total transaction of $521,193.15.
• On Monday, September 8th, Reprogrammed Interchange Llc sold 464,421 shares of Vor Biopharma stock. The stock was sold at an average price of $1.99, for a total transaction of $924,197.79.
• On Tuesday, September 9th, Reprogrammed Interchange Llc sold 449,226 shares of Vor Biopharma stock. The stock was sold at an average price of $2.00, for a total transaction of $898,452.00.
• On Friday, September 5th, Reprogrammed Interchange Llc sold 400,000 shares of Vor Biopharma stock. The stock was sold at an average price of $1.97, for a total transaction of $788,000.00.
• On Thursday, September 4th, Reprogrammed Interchange Llc sold 453,016 shares of Vor Biopharma stock. The stock was sold at an average price of $1.93, for a total transaction of $874,320.88.
• On Wednesday, September 3rd, Reprogrammed Interchange Llc sold 554,612 shares of Vor Biopharma stock. The shares were sold at an average price of $2.00, for a total transaction of $1,109,224.00.
• On Thursday, August 28th, Reprogrammed Interchange Llc sold 806,351 shares of Vor Biopharma stock. The shares were sold at an average price of $2.01, for a total transaction of $1,620,765.51.
• On Wednesday, August 27th, Reprogrammed Interchange Llc sold 611,647 shares of Vor Biopharma stock. The shares were sold at an average price of $2.01, for a total transaction of $1,229,410.47.

Vor Biopharma Stock Down 8.0%

VOR stock traded down $0.14 during trading on Monday, hitting $1.60. 6,009,423 shares of the company's stock traded hands, compared to its average volume of 7,617,477. The firm has a market capitalization of $202.69 million, a P/E ratio of -0.97 and a beta of 2.05. The business has a fifty day simple moving average of $2.09 and a two-hundred day simple moving average of $1.13. Vor Biopharma Inc. has a 1 year low of $0.13 and a 1 year high of $3.29.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. HC Wainwright reissued a "buy" rating and issued a $3.00 price target on shares of Vor Biopharma in a research report on Thursday, August 14th. Wedbush reissued an "outperform" rating on shares of Vor Biopharma in a research report on Thursday, June 26th. Five investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company's stock. According to MarketBeat, Vor Biopharma presently has an average rating of "Moderate Buy" and a consensus price target of $6.07.

Institutional Investors Weigh In On Vor Biopharma

Institutional investors have recently bought and sold shares of the company. Money Concepts Capital Corp boosted its stake in Vor Biopharma by 106.1% in the first quarter. Money Concepts Capital Corp now owns 51,535 shares of the company's stock valued at $37,000 after acquiring an additional 26,535 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in Vor Biopharma by 218.2% in the first quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company's stock valued at $61,000 after acquiring an additional 58,247 shares in the last quarter. XTX Topco Ltd acquired a new stake in Vor Biopharma in the second quarter valued at approximately $66,000. OMERS ADMINISTRATION Corp acquired a new stake in Vor Biopharma in the first quarter valued at approximately $100,000. Finally, Trustees of Columbia University in the City of New York acquired a new stake in Vor Biopharma in the fourth quarter valued at approximately $102,000. 97.29% of the stock is currently owned by institutional investors and hedge funds.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.